Table 1: Individual patient data.

Age [Years],
Sex
Age at
DLB Onset
[Years]
Medication
for DLB
[mg/day]
Age at
RBD Onset
[Years]
RBD
Duration
[Years]
PSQI 5(h) Motor and Vocal
Behavior after
12 Weeks of Tiaprid
Final
Tiaprid
Dosage
[mg]
Before After 12
Weeks
Patient Bed
Partner
72, male 68 levodopa/carbidopa 200/50
rivastigmine patch 4.6
66 6 3 1 + + 50*
73, male 70 levodopa/carbidopa 400/100
rivastigmine capsules 12
pramipexole 1,05
71 2 2 0 + + 100
78, male 72 levodopa/carbidopa 600/150
rivastigmine patch 9.5
rotigotine patch 8
75 3 2 2 = = 100
74, male 72 levodopa/carbidopa 400/100
rivastigmine patch 9.5
71 3 3 0 + + 50
71, female 70 levodopa/carbidopa 300/75
donepezil 5
70 1 2 1 + = 100
63, male 61 levodopa/carbidopa 300/75
donepezil 10
62 1 2 1 + + 150

The individual patient data for DLB (dementia with Lewy bodies) and RBM (REM sleep behavior disorder) are given. Under “PSQI 5(h)” the patients’ answers to item 5(h) of the Pittsburgh Sleep Quality Index are listed. The perception of the nighttime motor and vocal behavior of the patient by the patient himself and his bedpartner are coded as “+” (improved), “=” (unchanged), “-“ (deteriorated).
*: This patient initially experienced a substantial improvement of sleep under a dosage of 50 mg tiaprid. Subsequent to increasing the dosage to 100 mg, sleep deteriorated. After having returned to the initial dosage of 50 mg, sleep improved again.

Back to Article